keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant chemotherapy and breast cancer

keyword
https://www.readbyqxmd.com/read/28929593/efficacy-of-anthracycline-taxane-based-neo-adjuvant-chemotherapy-on-triple-negative-breast-cancer-in-brca1-brca2-mutation-carriers
#1
Lucie Bignon, Jean-Pierre Fricker, Catherine Nogues, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, Olivier Caron, Alain Lortholary, Laurence Faivre, Christine Lasset, Veronique Mari, Paul Gesta, Laurence Gladieff, Akila Hamimi, Thierry Petit, Michel Velten
This study aims to estimate the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. We carried out a retrospective analysis of 53 patients including 46 BRCA1, 6 BRCA2, and 1 combined BRCA1 and BRCA2 mutation. All patients had been diagnosed with triple-negative breast cancer (TNBC) between 1997 and 2014...
September 19, 2017: Breast Journal
https://www.readbyqxmd.com/read/28929359/immunohistochemical-versus-molecular-blueprint-and-mammaprint-subtyping-of-breast-carcinoma-outcome-results-from-the-eortc-10041-big-3-04-mindact-trial
#2
G Viale, F A de Snoo, L Slaets, J Bogaerts, L van 't Veer, E J Rutgers, M J Piccart-Gebhart, L Stork-Sloots, A Glas, L Russo, P Dell'Orto, K Tryfonidis, S Litière, F Cardoso
PURPOSE: This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined by the 2013 St. Gallen guidelines. METHODS: MS classified patients in the following subtypes: Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER, PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology (n = 5806)...
September 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28921379/time-trends-in-utilization-of-g-csf-prophylaxis-and-risk-of-febrile-neutropenia-in-a-medicare-population-receiving-adjuvant-chemotherapy-for-early-stage-breast-cancer
#3
Ravi K Goyal, Spiros Tzivelekis, Kenneth J Rothman, Sean D Candrilli, James A Kaye
PURPOSE: The purpose of this study is to assess temporal trends in the use of granulocyte colony-stimulating factor (G-CSF) prophylaxis and risk of febrile neutropenia (FN) among older women receiving adjuvant chemotherapy for early-stage breast cancer. METHODS: Women aged ≥ 66 years with diagnosis of early-stage breast cancer who initiated selected adjuvant chemotherapy regimens were identified using the SEER-Medicare data from 2002 to 2012. Adjusted, calendar-year-specific proportions were estimated for use of G-CSF primary prophylaxis (PP) and secondary prophylaxis and FN risk in the first and the second/subsequent cycles during the first course of chemotherapy, using logistic regression models...
September 18, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28913760/impact-of-histopathology-tumor-infiltrating-lymphocytes-and-adjuvant-chemotherapy-on-prognosis-of-triple-negative-breast-cancer
#4
Roberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, Judith A Gilbert, Victoria Cafourek, David W Hillman, Ahmed Elkhanany, Margaret Akinhanmi, Jenna Lilyquist, Abigail Thomas, Vivian Negron, Judy C Boughey, Minetta C Liu, James N Ingle, Krishna R Kalari, Fergus J Couch, Daniel W Visscher, Matthew P Goetz
BACKGROUND: Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown. METHODS: From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28912409/-a-case-of-pneumocystis-pneumonia-during-adjuvant-dose-dense-chemotherapy-for-breast-cancer
#5
Noriko Sagawa, Norie Abe, Tomohiko Ishimine, Hisamitsu Zaha
A 47-year-old woman received adjuvant chemotherapy for breast cancer. On the 13th day of 4 courses of dose-dense AC therapy, she developed a fever. She was orally administered an antibioticfor febrile neutropenia treatment. She showed no improvement of symptoms and gradually presented with new symptoms, including a non-productive cough and dyspnea. After admission, she underwent a further examination, and was provided a diagnosis of pneumocystis pneumonia. It is reported that patients receiving chemotherapy for solid tumors are less likely to develop opportunistic infections...
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28911092/concurrent-and-sequential-initiation-of-ovarian-function-suppression-with-chemotherapy-in-premenopausal-women-with-endocrine-responsive-early-breast-cancer-an-exploratory-analysis-of-text-and-soft
#6
M M Regan, B A Walley, P A Francis, G F Fleming, I Láng, H L Gómez, M Colleoni, C Tondini, G Pinotti, M Salim, S Spazzapan, V Parmar, T Ruhstaller, E A Abdi, R D Gelber, A S Coates, A Goldhirsch, O Pagani
Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28911063/stromal-lymphocyte-infiltration-after-neoadjuvant-chemotherapy-is-associated-with-aggressive-residual-disease-and-lower-disease-free-survival-in-her2-positive-breast-cancer
#7
A-S Hamy, J-Y Pierga, A Sabaila, E Laas, H Bonsang-Kitzis, C Laurent, A Vincent-Salomon, P Cottu, F Lerebours, R Rouzier, M Lae, F Reyal
Background: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910957/-effects-of-cell-cycle-regulatory-genes-on-breast-cancer-neo-adjuvant-chemotherapy-by-m-fish
#8
C Y Li, W Su, S Zhang, Y H Hu, J J Liu, J Zhang
Objective: The dysregulation of cell cycle could influence cell proliferation, differentiation and response to medicine. The purpose of this study is to explore the correlation between cell cycle regulatory genes and breast cancer neo-adjuvant chemotherapy (NAC) in patients with local advanced breast cancer, and thus to find some predictors of NAC to provide guidance for clinical treatment. Methods: Ninety five cases of local advanced breast cancer were collected, which were treated with NAC of TAC (Taxanes/Anthracycline/Cyclophosphamide) regimen...
September 12, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28903664/preferences-and-actual-chemotherapy-decision-making-in-the-greater-plains-collaborative-breast-cancer-study
#9
Ann M Berger, Russell J Buzalko, Kevin A Kupzyk, Bret J Gardner, Dilorom M Djalilova, Julie L Otte
INTRODUCTION: There is renewed interest in identifying breast cancer patients' participation in decision-making about adjuvant chemotherapy. There is a gap in the literature regarding the impact of these decisions on quality of life (QOL) and quality of care (QOC). Our aims were to determine similarities and differences in how patients diagnosed with breast cancer preferred to make decisions with providers about cancer treatment, to examine the patient's recall of her role when the decision was made about chemotherapy and to determine how preferred and actual roles, as well as congruence between them, relate to QOL and perceived QOC...
September 13, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28902882/risk-of-myeloid-neoplasms-after-radiotherapy-among-older-women-with-localized-breast-cancer-a-population-based-study
#10
Amer M Zeidan, Jessica B Long, Rong Wang, Xin Hu, James B Yu, Scott F Huntington, Gregory A Abel, Sarah S Mougalian, Nikolai A Podoltsev, Steven D Gore, Cary P Gross, Xiaomei Ma, Amy J Davidoff
BACKGROUND: There are inconsistent and limited data regarding the risk of myeloid neoplasms (MN) among breast cancer survivors who received radiotherapy (RT) in the absence of chemotherapy. Concern about subsequent MN might influence the decision to use adjuvant RT for women with localized disease. As patients with therapy-related MN have generally poor outcomes, the presumption of subsequent MN being therapy-related could affect treatment recommendations. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to study older women with in-situ or stage 1-3 breast cancer diagnosed 2001-2009 who received surgery...
2017: PloS One
https://www.readbyqxmd.com/read/28900632/clinical-outcomes-in-er-her2-node-positive-breast-cancer-patients-who-were-treated-according-to-the-recurrence-score-results-evidence-from-a-large-prospectively-designed-registry
#11
Salomon M Stemmer, Mariana Steiner, Shulamith Rizel, David B Geffen, Bella Nisenbaum, Tamar Peretz, Lior Soussan-Gutman, Avital Bareket-Samish, Kevin Isaacs, Ora Rosengarten, Georgeta Fried, Debbie McCullough, Christer Svedman, Steven Shak, Nicky Liebermann, Noa Ben-Baruch
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence Score-tested through Clalit Health Services from 1/2006 through 12/2011 (N = 709). Medical records were reviewed to verify treatments/recurrences/survival. Median follow-up, 5.9 years; median age, 62 years; 53.9% grade 2; 69.8% tumors ≤ 2 cm; 84.5% invasive ductal carcinoma; 42...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28894982/severe-depression-more-common-in-patients-with-ductal-carcinoma-in-situ-than-early-stage-invasive-breast-cancer-patients
#12
M L Gregorowitsch, H J G D van den Bongard, D A Young-Afat, J P Pignol, C H van Gils, A M May, H M Verkooijen
PURPOSE: Ductal carcinoma in situ (DCIS) is associated with an excellent prognosis; historical studies have shown similar levels of psychological distress in patients with DCIS and with early-stage invasive breast cancer (early-IBC). It is suggested that these results might have led to better patient education about prognosis after DCIS. This study reports the current levels of anxiety, depression, and health-related quality of life (HRQoL) in DCIS and early-IBC patients. METHODS: DCIS (n = 89) and early-IBC patients, T1-2N0, (n = 361) were selected from the UMBRELLA breast cancer cohort...
September 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28893260/long-lasting-complete-response-status-of-advanced-stage-iv-gall-bladder-cancer-and-colon-cancer-after-combined-treatment-including-autologous-formalin-fixed-tumor-vaccine-two-case-reports
#13
Yuki Imaoka, Fumito Kuranishi, Tsubasa Miyazaki, Hiroko Yasuda, Tadao Ohno
BACKGROUND: The prognosis of advanced (stage IV) cancer of the digestive organs is very poor. We have previously reported a case of advanced breast cancer with bone metastasis that was successfully treated with combined treatments including autologous formalin-fixed tumor vaccine (AFTV). Herein, we report the success of this approach in advanced stage IV (heavily metastasized) cases of gall bladder cancer and colon cancer. CASE PRESENTATION: Case 1: A 61-year-old woman with stage IV gall bladder cancer (liver metastasis and lymph node metastasis) underwent surgery in May 2011, including partial resection of the liver...
September 11, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28893026/superior-vena-cava-as-gateway-to-heart-metastatic-breast-carcinoma-causing-ball-in-a-loop-metastasis-to-right-atrium
#14
Harpreet Singh Sandhu, Sampath Kumar Mahadevappa Mahendrakar, Sulaiman Sadruddin Ladhani, Azizullah Hafizullah Khan, Yunus Shafi Loya
Breast carcinoma is the most common invasive cancer in women worldwide. It metastasizes commonly to bone, lungs, regional lymph nodes and brain. Cardiac metastasis of lung and breast cancers is a known but rare complication of advanced disease with tumour metastasising to pericardium via the locoregional lymphatic system. Here we present a case of 59-year-old female presenting with right upper limb oedema, facial puffiness and features of Superior Vena Cava (SVC) syndrome 15 years after mastectomy and adjuvant chemotherapy, radiotherapy for carcinoma of the right breast...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28890124/-sentinel-lymph-node-biopsy-and-neoadjuvant-treatment-in-breast-cancer
#15
REVIEW
Martha Duraes, Eugénie Guillot, Julien Seror, Nicolas Pouget, Roman Rouzier
Sentinel lymph node biopsy has replaced axillary lymph node dissection in those patients with clinically node-negative axilla without compromising their oncologic outcomes. Indication of neoadjuvant chemotherapy has been extended to patients to evaluate the pathologic response and to offer more conservative breast surgery. Sentinel lymph node dissection after neoadjuvant chemotherapy is feasible and accurate in patients with clinically node-negative patients. The timing of the sentinel lymph node biopsy, before or after medical treatment has been studied with benefits for each procedure...
September 7, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28888915/a-case-report-of-locally-advanced-triple-negative-breast-cancer-showing-pathological-complete-response-to-weekly-paclitaxel-with-bevacizumab-treatment-following-disease-progression-during-anthracycline-based-neoadjuvant-chemotherapy
#16
Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, Taizo Hirata
INTRODUCTION: Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced triple negative breast cancer, however, approximately 5% of cases show disease progression during NAC. Although downstaging is essential to create an opportunity for curative surgery and to improve the local control outcome in such a case, no additional line of chemotherapy has been established. CASE PRESENTATION: A 60-year-old woman was referred to our hospital for an axillary mass presenting three weeks ago and was diagnosed as having right locally advanced (T2N2M0, stage IIIA) triple negative breast cancer...
September 1, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28888809/childhood-maltreatment-psychological-resources-and-depressive-symptoms-in-women-with-breast-cancer
#17
Kate Ryan Kuhlman, Chloe C Boyle, Michael R Irwin, Patricia A Ganz, Catherine M Crespi, Arash Asher, Laura Petersen, Julienne E Bower
Childhood maltreatment is associated with elevated risk for depression across the human lifespan. Identifying the pathways through which childhood maltreatment relates to depressive symptoms may elucidate intervention targets that have the potential to reduce the lifelong negative health sequelae of maltreatment exposure. In this cross-sectional study, 271 women with early-stage breast cancer were assessed after their diagnosis but before the start of adjuvant treatment (chemotherapy, radiation, endocrine therapy)...
September 7, 2017: Child Abuse & Neglect
https://www.readbyqxmd.com/read/28884470/breast-conserving-therapy-and-mastectomy-revisited-breast-cancer-specific-survival-and-the-influence-of-prognostic-factors-in-129-692-patients
#18
Mirelle Lagendijk, Marissa C van Maaren, Sepideh Saadatmand, Luc Ja Strobbe, Philip Mp Poortmans, Linetta B Koppert, Madeleine Ma Tilanus-Linthorst, Sabine Siesling
This large population-based study compared breast-conserving surgery with radiation therapy (BCT) with mastectomy on (long-term) breast cancer-specific (BCSS) and overall survival (OS), and investigated the influence of several prognostic factors. Patients with primary T1-2N0-2M0 breast cancer, diagnosed between 1999-2012, were selected from the Netherlands Cancer Registry. We investigated the 1999-2005 (long-term outcome) and the 2006-2012 cohort (contemporary adjuvant systemic therapy). Cause of death was derived from the Statistics Netherlands (CBS)...
September 7, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28884392/socioeconomic-status-and-breast-cancer-treatment
#19
REVIEW
Marie S Dreyer, Ann B Nattinger, Emily L McGinley, Liliana E Pezzin
PURPOSE: Evidence suggests substantial disparities in breast cancer survival by socioeconomic status (SES). We examine the extent to which receipt of newer, less invasive, or more effective treatments-a plausible source of disparities in survival-varies by SES among elderly women with early-stage breast cancer. METHODS: Multivariate regression analyses applied to 11,368 women (age 66-90 years) identified from SEER-Medicare as having invasive breast cancer diagnosed in 2006-2009...
September 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28882552/prognostic-and-predictive-biomarkers-in-breast-cancer-past-present-and-future
#20
REVIEW
Andrea Nicolini, Paola Ferrari, Michael J Duffy
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncotype DX and MammaPrint, may be used for predicting outcome and aiding adjunct therapy decision making in patients with ER-positive, HER2-negative breast cancers that are either lymph node-negative or node positive (1-3 metastatic nodes), while uPA/PAI-1 may be similarly used in ER-positive, lymph node-negative patients...
September 4, 2017: Seminars in Cancer Biology
keyword
keyword
31152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"